Elicera Therapeutics AB (OSTO:ELIC) Float Percentage Of Total Shares Outstanding: 0.00% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ELIC Elicera Therapeutics AB OSTO:ELIC
25 GF Score
Price kr2.62
! 1 Warning Sign
View Full Analysis

What is Elicera Therapeutics AB Float Percentage Of Total Shares Outstanding?

Elicera Therapeutics AB OSTO:ELIC -1.50% 25 Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 16, 2026. GuruFocus rates OSTO:ELIC with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Elicera Therapeutics AB's float shares is 0.00 Mil. Elicera Therapeutics AB's total shares outstanding is 66.74 Mil. Elicera Therapeutics AB's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Elicera Therapeutics AB's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Elicera Therapeutics AB's Institutional Ownership is 0.02%.

OSTO:ELIC
25GF Score
Elicera Therapeutics AB OSTO:ELIC
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicera Therapeutics AB Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Elicera Therapeutics AB's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/66.74
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 0.00% mean?
Elicera Therapeutics AB (OSTO:ELIC) has a Float Percentage Of Total Shares Outstanding of 0.00% as of Jul. 16, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Elicera Therapeutics AB and its competitors.
Is Elicera Therapeutics AB's Float Percentage Of Total Shares Outstanding too high?
Elicera Therapeutics AB's current Float Percentage Of Total Shares Outstanding is 0.00%. Overall, Elicera Therapeutics AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Elicera Therapeutics AB's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
Elicera Therapeutics AB's Float Percentage Of Total Shares Outstanding of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Elicera Therapeutics AB and its competitors. Elicera Therapeutics AB's current Float Percentage Of Total Shares Outstanding is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicera Therapeutics AB stock overvalued right now?
Elicera Therapeutics AB (OSTO:ELIC) has a current Float Percentage Of Total Shares Outstanding of 0.00%. The current Float Percentage Of Total Shares Outstanding is 0.00%. Elicera Therapeutics AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Elicera Therapeutics AB (OSTO:ELIC), the current Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicera Therapeutics AB Business Description

Other Exchanges 8E8:Germany
Address Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, 412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Its product portfolio consists of four drug candidates, including two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to the universal CAR T-cell technology platform, iTANK (ELC-001). The Company is running four internal immunotherapy development projects, comprising two CAR T-cell programs and two oncolytic virus programs.
25GF Score

Get the complete analysis for OSTO:ELIC

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.62
Price